How long does it take to lose 10kg on Wegovy?

What the trial data shows about the pace of weight loss

The STEP 1 trial is the clearest window we have into Wegovy's real-world timeline. Over 68 weeks, adults with obesity who took semaglutide 2.4mg lost an average of around 15% of body weight, compared to roughly 2.4% with placebo. That is an important number, but it hides a lot about timing. Weight loss in GLP-1 trials tends to be front-loaded: the most rapid change happens in the first 12 to 20 weeks, then the rate slows as the body approaches a new equilibrium. By around week 20, many participants had already lost a meaningful proportion of their eventual total, which is why, for someone whose 10kg target sits within that 15% average, the four-to-seven month window is a reasonable working estimate rather than a guarantee.

It is also worth noting that the titration schedule matters here. Wegovy starts at 0.25mg and steps up through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg maintenance, with approximately four weeks at each level. That means a patient does not reach the full therapeutic dose until around week 16 at the earliest. Weight loss during those first few months tends to be more modest precisely because the dose is building. If you have come to this page hoping for a tight deadline, that context is genuinely useful: the medicine is doing something during titration, just not yet at full strength. You can read more about how the overall timeline unfolds in our guide to how quickly Wegovy starts to work.

Why 10kg means something different for each person

A target of 10kg is not a percentage, it is an absolute number. That distinction matters more than it might seem. For someone starting at 90kg, 10kg represents about 11% of body weight. The STEP 1 data suggests many participants reached that threshold during active treatment. For someone starting at 120kg, 10kg is only around 8%, and would typically be reached earlier in the curve. Someone at 130kg might reach 10kg lost before the full maintenance dose is even established.

Starting weight is the single biggest predictor of how quickly an absolute-kilogram target is crossed. Beyond that, the literature points to a few consistent factors: people who tolerate the titration well and experience fewer gastrointestinal side effects tend to stay on schedule; those who pair treatment with reduced calorie intake and regular activity generally see faster and more sustained results; and those who need dose adjustments due to side effects may spend longer at a lower dose, which slows the rate of loss. None of this is a reason to push through side effects unsupported. It is exactly the kind of thing a prescriber discusses with you, and a question our clinical team hears most weeks. If you are wondering when to expect the first noticeable change, that is a slightly different question with a different answer.

The 7.2mg dose and what it changes about expectations

In January 2026 the MHRA approved a higher 7.2mg maintenance dose of Wegovy, with a dedicated single-dose pen following in April 2026. Trial data for 7.2mg showed an average weight loss of around 20.7% over 72 weeks, approaching tirzepatide's results in some analyses. That higher dose narrows the gap between the two licensed injectable treatments and raises an obvious question: does it also change the timeline for a 10kg goal? The honest answer is yes, potentially. A greater eventual weight loss, achieved through a higher maintenance dose, tends to correlate with steeper loss in the middle phases of treatment. The titration schedule still starts at 0.25mg, so the early weeks are unchanged; it is the sustained rate from around week 16 onward that may accelerate. For people with a larger amount to lose, our page on how long it takes to lose 20kg on Wegovy gives a useful sense of what the extended arc looks like at higher doses. You can find a broader overview of how the two injections compare on our Wegovy treatment page.

One thing the 7.2mg approval does not change: these are prescription-only medicines, and which dose is appropriate is a clinical decision made by a prescriber based on your individual response and tolerability. NICE's appraisal of semaglutide for weight management (TA875) sets out the clinical framework. Specific dose availability is confirmed at consultation.

What a realistic personal timeline actually looks like

If you are reading this page, there is a reasonable chance you have been researching for a while, perhaps looking at waiting lists or weighing up whether private treatment makes sense. That is a completely understandable place to be. The trial evidence gives you a range rather than a date, and that can feel frustrating when you have a specific goal in mind.

What the data does allow is a working framework. The titration phase (the first 16 weeks) is the settling-in period; expect steady rather than dramatic change. Weeks 16 to 32 tend to show the steepest absolute loss for most people. By six months at maintenance dose, the majority of participants who will reach a 10kg loss have done so. Beyond that, the rate slows but continues. If weight loss is less than 5% after six months at the highest tolerated dose, that is a clinical signal to review whether treatment should continue, which is exactly what a prescriber would look at. For a broader sense of how the overall journey is structured, the full weight-loss timeline page covers the longer arc in more detail.

Private treatment through a regulated pharmacy means no referral required, no waiting list, and a clinical review before every repeat. If you are thinking about cost, there is useful context on how Wegovy private pricing compares across providers. When you are ready to find out whether treatment is suitable for you specifically, a free consultation with one of our prescribers is the place to start.